- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.10. | Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment | 1 | Insider Monkey | ||
| 30.09. | Jones Trading initiates coverage on Aardvark Therapeutics stock with Buy rating | 2 | Investing.com | ||
| 23.09. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum | 2 | GlobeNewswire (USA) | ||
| 23.09. | H.C. Wainwright reiterates Buy rating on Aardvark Therapeutics stock | 1 | Investing.com | ||
| 21.08. | Cantor Fitzgerald bestätigt "Overweight"-Rating für Aardvark Therapeutics und sieht über 400 % Kurspotenzial | 4 | Investing.com Deutsch | ||
| 21.08. | Cantor Fitzgerald reiterates Overweight rating on Aardvark Therapeutics stock | 2 | Investing.com | ||
| 14.08. | Cantor Fitzgerald: Erfolgschancen der Phase-3-Studie von Aardvark Therapeutics massiv unterbewertet | 8 | Investing.com Deutsch | ||
| 14.08. | Cantor Fitzgerald reiterates Overweight rating on Aardvark Therapeutics stock | 2 | Investing.com | ||
| AARDVARK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.08. | Aardvark Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.08. | Aardvark Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates | 89 | GlobeNewswire (Europe) | Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients discontinuing... ► Artikel lesen | |
| 12.08. | Aardvark Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following ... | 171 | GlobeNewswire (Europe) | In a gold-standard model of obesity, treatment with ARD-201 resulted in approximately 19% body weight reduction after 30 days of treatment.ARD-201 was also associated with attenuated weight regain... ► Artikel lesen | |
| 18.07. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) | 159 | GlobeNewswire (Europe) | SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics... ► Artikel lesen | |
| 30.06. | H.C. Wainwright nimmt Aardvark Therapeutics-Aktie mit Kaufempfehlung auf | 3 | Investing.com Deutsch | ||
| 30.06. | H.C. Wainwright initiates coverage on Aardvark Therapeutics stock with Buy rating | 1 | Investing.com | ||
| 19.05. | Aardvark Therapeutics strukturiert Führungsteam während Phase-3-Studie um | 2 | Investing.com Deutsch | ||
| 19.05. | Aardvark Therapeutics reshuffles leadership amid Phase 3 study | 2 | Investing.com | ||
| 19.05. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions | 213 | GlobeNewswire (Europe) | Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian... ► Artikel lesen | |
| 15.05. | Aardvark Therapeutics reports Q1 results | 2 | Seeking Alpha |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,270 | +0,49 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 48,550 | +3,61 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| ARCELLX | 84,07 | +0,85 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 6,590 | 0,00 % | Ventyx Biosciences: NBC feiert Daten-Knall und +928% in 6 Monaten | Der Party-Herbst reißt nicht ab: Nach dem Tenbagger Minerva explodieren im No Brainer Club die nächsten Kurs-Granaten. Eine davon ist die Aktie von Ventyx Biosciences. Die Ventyx-Aktie hatte der No... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,250 | +0,53 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 57,76 | +3,53 % | Mizuho startet Coverage für Kymera Therapeutics mit "Outperform" | ||
| HARMONY BIOSCIENCES | 29,600 | +12,68 % | Harmony Biosciences Rises 10.6% On Strong Q3 WAKIX Results And Upgraded Guidance | ||
| NUVALENT | 90,89 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| TANGO THERAPEUTICS | 7,510 | 0,00 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces $225 Million Financing | BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| NURIX THERAPEUTICS | 10,400 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia | 600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,720 | 0,00 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| 89BIO | 14,800 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| EVOTEC | 6,866 | +2,08 % | Evotec Aktie: Gefährlich! Breakversuch scheint erneut zu scheitern | Wieder läuft die Evotec Aktie auf massive charttechnische Hindernisse an der 7-Euro-Marke an - und wieder könnte sie scheitern. Im Handel am Donnerstag erreichte die Biotech-Aktie auf XETRA in der Spitze... ► Artikel lesen | |
| COGENT BIOSCIENCES | 14,840 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib | Detailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this... ► Artikel lesen | |
| MAZE THERAPEUTICS | 29,900 | +2,54 % | Maze Therapeutics files to sell 9.23M shares of common stock for holders |
Das Unternehmen AARDVARK THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 10,820 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AARDVARK THERAPEUTICS INC finden Sie auf Wallstreet Online.